A research investigation has devised an innovative targeted drug delivery system employing DCLK1-functionalized, folic acid-conjugated HST encapsulated within chitosan nanoparticles (CFH-DCLK1) to preferentially target cancer stem cells (CSCs) within the context of CRC. Here, DCLK1 is linked to cancer.